[Beta blockaders and general pathology].
The authors review the literature on the undesirable side effects of beta blockaders (excluding the cardiovascular system) and report the new therapeutic propects in psychiatry and in various metabolic disorders. The necessity of sufficient follow up made us choose propanolol as reference product without neglecting acebutolol, pindolol and oxprenolol.
D000070:Acebutolol / Q000652:urine; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D001249:Asthma / Q000139:chemically induced; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D006943:Hyperglycemia / Q000139:chemically induced; D007003:Hypoglycemia / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000139:chemically induced; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000139:chemically induced; D009440:Neurasthenia / Q000139:chemically induced; D010927:Placental Insufficiency / Q000139:chemically induced; D011217:Practolol / Q000009:adverse effects; D011247:Pregnancy; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use; D014202:Tremor / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000319:Adrenergic beta-Antagonists; D000070:Acebutolol; D011433:Propranolol; D011217:Practolol
Bêta-bloquants et pathologie générale